Hair Growth Supplement

Nutrafol Women Hair Growth Nutraceutical

58 adverse event reports submitted to the FDA · 2023–2025 · Data current as of June 3, 2026

These are reports submitted to the FDA. A report does not mean the product caused the effect. Counts reflect reporting activity, not how common an effect is.

Most Reported Reactions

Top 10 reactions from 58 reports. One report may include multiple reactions — reaction totals may exceed the report count.

Hepatic enzyme increased

Abdominal pain

Nephrolithiasis

Dizziness

Palpitations

Nausea

Hypersensitivity

Pain

Pruritus

Rash

Reported Outcomes

Outcome categories as recorded in FDA reports. One report may include multiple outcomes.

Outcome	Reports
Other Serious or Important Medical Event	53
Hospitalization	13
Other Serious Outcome	9
Visited Emergency Room	6
Allergic Reaction	5
Visited a Health Care Provider	2
Life Threatening	2
Required Intervention	1

Who Reported

Reporter demographics where available. Many reports do not include age or gender data.

Age

Under 18

18–34

35–49

50–64

65–79

80+

Unknown

24 reports had age data; 34 unknown.

Gender

Female

Unknown/Not Reported

Reports by Year

Annual report counts from 2023–2025. Spike years may reflect recalls, media coverage, or litigation rather than changes in the product.

'23

'24

'25

Hover bars for exact counts.

Context about this data: Reports heavily concentrated in 2025 (64% of total). High concentration may reflect a recall, enforcement action, batch filing, or litigation-driven reporting rather than ongoing consumer use.

← View all Nutrafol products in FDA data

Data Source

This page presents data from the FDA's CFSAN Adverse Event Reporting System (CAERS) via the openFDA API. Reports are voluntary and unverified. The FDA has not concluded that this product caused any reported event.

View openFDA CAERS data ↗ · About our methodology · How to read this data